Louise Chen
Stock Analyst at Scotiabank
(3.19)
# 1,179
Out of 5,032 analysts
300
Total ratings
45.99%
Success rate
1.67%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $22.51 | +255.40% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.90 | +373.68% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $15.06 | -7.01% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.87 | +541.71% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $17.27 | +218.47% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $65.95 | -16.60% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $4.49 | +234.08% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $73.15 | -31.65% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.03 | +198.21% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $16.39 | +3.72% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $47.89 | +46.17% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $16.38 | +205.25% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $10.05 | +198.51% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $28.27 | +94.59% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.21 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $54.37 | +194.28% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $42.39 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $229.57 | +4.54% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.51 | +83.60% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $193.22 | +11.27% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.81 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $84.79 | +82.80% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.26 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $802.83 | +10.24% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.40 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.51 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.07 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.90 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $101.52 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.98 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.64 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.64 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.93 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $578.05 | +60.02% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.75 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.71 | +1,652.02% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.73 | +189.02% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $5.77 | +333.28% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.08 | +231.56% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $20.88 | +139.46% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.25 | +300.00% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.38 | +2,279.69% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.08 | +81,129,707.69% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $286.67 | -10.00% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $19.31 | -22.32% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.29 | +3,775.97% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.52 | +1,215.79% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.17 | +527.62% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $22.51
Upside: +255.40%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.90
Upside: +373.68%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $15.06
Upside: -7.01%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.87
Upside: +541.71%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $17.27
Upside: +218.47%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $65.95
Upside: -16.60%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.49
Upside: +234.08%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $73.15
Upside: -31.65%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.03
Upside: +198.21%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $16.39
Upside: +3.72%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $47.89
Upside: +46.17%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $16.38
Upside: +205.25%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $10.05
Upside: +198.51%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $28.27
Upside: +94.59%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.21
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $54.37
Upside: +194.28%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $42.39
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $229.57
Upside: +4.54%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.51
Upside: +83.60%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $193.22
Upside: +11.27%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.81
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $84.79
Upside: +82.80%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.26
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $802.83
Upside: +10.24%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.40
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.51
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.07
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.90
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $101.52
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.98
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.64
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.64
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.93
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $578.05
Upside: +60.02%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.75
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.71
Upside: +1,652.02%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.73
Upside: +189.02%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $5.77
Upside: +333.28%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.08
Upside: +231.56%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $20.88
Upside: +139.46%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.25
Upside: +300.00%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.38
Upside: +2,279.69%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.08
Upside: +81,129,707.69%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $286.67
Upside: -10.00%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $19.31
Upside: -22.32%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.29
Upside: +3,775.97%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.52
Upside: +1,215.79%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.17
Upside: +527.62%